GRAIL, Inc. Common Stock (NASDAQ: GRALV) Stock Competitors & Peer Comparison
See GRALV's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GRALV and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRALV | $18.63 | +8.19% | 579.4M | N/A | N/A | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.63% |
| TMO | $673.97 | -0.15% | 250.9B | 29.30 | $23.16 | +0.27% |
| DHR | $224.28 | -0.09% | 159.9B | 28.50 | $7.98 | +0.63% |
| NTRA | $413.45 | +0.21% | 59B | -311.95 | -$1.32 | N/A |
| A | $174.85 | +1.19% | 49.5B | 30.15 | $5.81 | +0.58% |
| IQV | $268.73 | -0.61% | 44.6B | 22.32 | $12.13 | N/A |
| WAT | $441.99 | +1.95% | 43.5B | 32.38 | $13.68 | N/A |
| IDXX | $528.93 | +1.86% | 41.7B | 37.21 | $14.22 | N/A |
| ILMN | $270.26 | +0.10% | 41.1B | 54.06 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
GRALV vs DHR-PB Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GRALV's ROE is N/A, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
GRALV vs TMO Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, TMO has a market cap of 250.9B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while TMO trades at $673.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas TMO's P/E ratio is 29.30. In terms of profitability, GRALV's ROE is N/A, compared to TMO's ROE of +0.13%. Regarding short-term risk, GRALV is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
GRALV vs DHR Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR has a market cap of 159.9B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while DHR trades at $224.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR's P/E ratio is 28.50. In terms of profitability, GRALV's ROE is N/A, compared to DHR's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
GRALV vs NTRA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NTRA has a market cap of 59B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NTRA trades at $413.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NTRA's P/E ratio is -311.95. In terms of profitability, GRALV's ROE is N/A, compared to NTRA's ROE of -0.12%. Regarding short-term risk, GRALV is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
GRALV vs A Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, A has a market cap of 49.5B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while A trades at $174.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas A's P/E ratio is 30.15. In terms of profitability, GRALV's ROE is N/A, compared to A's ROE of +0.20%. Regarding short-term risk, GRALV is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
GRALV vs IQV Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IQV has a market cap of 44.6B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while IQV trades at $268.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IQV's P/E ratio is 22.32. In terms of profitability, GRALV's ROE is N/A, compared to IQV's ROE of +0.22%. Regarding short-term risk, GRALV is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check IQV's competition here
Waters Corporation (NYSE: WAT)
GRALV vs WAT Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while WAT trades at $441.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas WAT's P/E ratio is 32.38. In terms of profitability, GRALV's ROE is N/A, compared to WAT's ROE of +0.02%. Regarding short-term risk, GRALV is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
GRALV vs IDXX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while IDXX trades at $528.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IDXX's P/E ratio is 37.21. In terms of profitability, GRALV's ROE is N/A, compared to IDXX's ROE of +0.72%. Regarding short-term risk, GRALV is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
GRALV vs ILMN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ILMN has a market cap of 41.1B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ILMN trades at $270.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ILMN's P/E ratio is 54.06. In terms of profitability, GRALV's ROE is N/A, compared to ILMN's ROE of +0.31%. Regarding short-term risk, GRALV is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
GRALV vs MTD Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MTD has a market cap of 31.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MTD trades at $1,531.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MTD's P/E ratio is 35.50. In terms of profitability, GRALV's ROE is N/A, compared to MTD's ROE of -12.00%. Regarding short-term risk, GRALV is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
GRALV vs DGX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while DGX trades at $235.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DGX's P/E ratio is 23.44. In terms of profitability, GRALV's ROE is N/A, compared to DGX's ROE of +0.14%. Regarding short-term risk, GRALV is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
GRALV vs LH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while LH trades at $308.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LH's P/E ratio is 18.37. In terms of profitability, GRALV's ROE is N/A, compared to LH's ROE of +0.12%. Regarding short-term risk, GRALV is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
GRALV vs GH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GH has a market cap of 23.8B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while GH trades at $176.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GH's P/E ratio is -50.81. In terms of profitability, GRALV's ROE is N/A, compared to GH's ROE of +2.11%. Regarding short-term risk, GRALV is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
GRALV vs EXAS Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GRALV's ROE is N/A, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GRALV is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
GRALV vs MEDP Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MEDP has a market cap of 17.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MEDP trades at $620.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MEDP's P/E ratio is 36.10. In terms of profitability, GRALV's ROE is N/A, compared to MEDP's ROE of +1.10%. Regarding short-term risk, GRALV is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
GRALV vs ILMNV Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to ILMNV's ROE of N/A. Regarding short-term risk, GRALV is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
GRALV vs RVTY Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, RVTY has a market cap of 16.8B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while RVTY trades at $150.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas RVTY's P/E ratio is 28.22. In terms of profitability, GRALV's ROE is N/A, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GRALV is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
GRALV vs PKI Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PKI's P/E ratio is 41.45. In terms of profitability, GRALV's ROE is N/A, compared to PKI's ROE of +0.03%. Regarding short-term risk, GRALV is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
GRALV vs CRL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CRL has a market cap of 14.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CRL trades at $291.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CRL's P/E ratio is 29.77. In terms of profitability, GRALV's ROE is N/A, compared to CRL's ROE of -0.08%. Regarding short-term risk, GRALV is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
GRALV vs ICLR Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ICLR trades at $171.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ICLR's P/E ratio is 14.32. In terms of profitability, GRALV's ROE is N/A, compared to ICLR's ROE of +0.04%. Regarding short-term risk, GRALV is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
GRALV vs QGEN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, QGEN has a market cap of 9.3B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while QGEN trades at $44.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas QGEN's P/E ratio is 18.60. In terms of profitability, GRALV's ROE is N/A, compared to QGEN's ROE of +0.12%. Regarding short-term risk, GRALV is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
GRALV vs GRAL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while GRAL trades at $134.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GRAL's P/E ratio is -13.60. In terms of profitability, GRALV's ROE is N/A, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GRALV is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
GRALV vs RDNT Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while RDNT trades at $70.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas RDNT's P/E ratio is 156.11. In terms of profitability, GRALV's ROE is N/A, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GRALV is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
GRALV vs BLLN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BLLN has a market cap of 5.6B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BLLN trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BLLN's P/E ratio is 173.89. In terms of profitability, GRALV's ROE is N/A, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
GRALV vs SHC Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while SHC trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SHC's P/E ratio is 19.22. In terms of profitability, GRALV's ROE is N/A, compared to SHC's ROE of +0.27%. Regarding short-term risk, GRALV is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
GRALV vs SYNH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GRALV's ROE is N/A, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
GRALV vs VCYT Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while VCYT trades at $45.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 22.62. In terms of profitability, GRALV's ROE is N/A, compared to VCYT's ROE of +0.09%. Regarding short-term risk, GRALV is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
GRALV vs CDNA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CDNA trades at $63.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CDNA's P/E ratio is 76.90. In terms of profitability, GRALV's ROE is N/A, compared to CDNA's ROE of +0.33%. Regarding short-term risk, GRALV is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
GRALV vs OLK Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas OLK's P/E ratio is -96.59. In terms of profitability, GRALV's ROE is N/A, compared to OLK's ROE of -0.07%. Regarding short-term risk, GRALV is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
GRALV vs WGS Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while WGS trades at $78.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas WGS's P/E ratio is 238.69. In terms of profitability, GRALV's ROE is N/A, compared to WGS's ROE of -0.39%. Regarding short-term risk, GRALV is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
GRALV vs PSNL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while PSNL trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PSNL's P/E ratio is -14.97. In terms of profitability, GRALV's ROE is N/A, compared to PSNL's ROE of -0.46%. Regarding short-term risk, GRALV is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
GRALV vs OPK Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas OPK's P/E ratio is -6.04. In terms of profitability, GRALV's ROE is N/A, compared to OPK's ROE of -0.06%. Regarding short-term risk, GRALV is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
GRALV vs CSTL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CSTL trades at $34.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CSTL's P/E ratio is -54.44. In terms of profitability, GRALV's ROE is N/A, compared to CSTL's ROE of -0.04%. Regarding short-term risk, GRALV is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
GRALV vs FLGT Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, FLGT has a market cap of 635M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while FLGT trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas FLGT's P/E ratio is 2236.00. In terms of profitability, GRALV's ROE is N/A, compared to FLGT's ROE of -0.08%. Regarding short-term risk, GRALV is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
GRALV vs NEO Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NEO has a market cap of 495.7M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NEO trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NEO's P/E ratio is 148.38. In terms of profitability, GRALV's ROE is N/A, compared to NEO's ROE of -0.06%. Regarding short-term risk, GRALV is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
GRALV vs MYGN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MYGN has a market cap of 400.5M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MYGN's P/E ratio is -32.62. In terms of profitability, GRALV's ROE is N/A, compared to MYGN's ROE of -0.33%. Regarding short-term risk, GRALV is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
GRALV vs CO Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CO's P/E ratio is 5.06. In terms of profitability, GRALV's ROE is N/A, compared to CO's ROE of +0.11%. Regarding short-term risk, GRALV is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
GRALV vs FLDM Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GRALV's ROE is N/A, compared to FLDM's ROE of +0.18%. Regarding short-term risk, GRALV is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
GRALV vs BDSX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BDSX has a market cap of 247.6M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BDSX trades at $30.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BDSX's P/E ratio is -9.60. In terms of profitability, GRALV's ROE is N/A, compared to BDSX's ROE of -7.88%. Regarding short-term risk, GRALV is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
GRALV vs XGN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while XGN trades at $8.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas XGN's P/E ratio is -10.47. In terms of profitability, GRALV's ROE is N/A, compared to XGN's ROE of -1.22%. Regarding short-term risk, GRALV is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
GRALV vs FRNM Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, FRNM has a market cap of 132.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while FRNM trades at $15.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas FRNM's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to FRNM's ROE of N/A. Regarding short-term risk, GRALV is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
GRALV vs GTH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GTH's P/E ratio is -1.11. In terms of profitability, GRALV's ROE is N/A, compared to GTH's ROE of -1.01%. Regarding short-term risk, GRALV is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
GRALV vs GENE Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GENE's P/E ratio is -38.25. In terms of profitability, GRALV's ROE is N/A, compared to GENE's ROE of -1.85%. Regarding short-term risk, GRALV is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
GRALV vs IMDX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IMDX has a market cap of 102.7M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while IMDX trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IMDX's P/E ratio is -2.13. In terms of profitability, GRALV's ROE is N/A, compared to IMDX's ROE of +2.72%. Regarding short-term risk, GRALV is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
GRALV vs SERA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SERA has a market cap of 77.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while SERA trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SERA's P/E ratio is -3.11. In terms of profitability, GRALV's ROE is N/A, compared to SERA's ROE of -0.47%. Regarding short-term risk, GRALV is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
GRALV vs PRPO Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while PRPO trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRPO's P/E ratio is -37.09. In terms of profitability, GRALV's ROE is N/A, compared to PRPO's ROE of -0.08%. Regarding short-term risk, GRALV is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
GRALV vs QUCY Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, QUCY has a market cap of 31.2M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas QUCY's P/E ratio is -0.06. In terms of profitability, GRALV's ROE is N/A, compared to QUCY's ROE of -3.65%. Regarding short-term risk, GRALV is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
GRALV vs MDXH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MDXH has a market cap of 28.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MDXH trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MDXH's P/E ratio is -0.75. In terms of profitability, GRALV's ROE is N/A, compared to MDXH's ROE of +1.43%. Regarding short-term risk, GRALV is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
GRALV vs AKU Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas AKU's P/E ratio is -0.13. In terms of profitability, GRALV's ROE is N/A, compared to AKU's ROE of -5.32%. Regarding short-term risk, GRALV is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
GRALV vs BNR Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BNR has a market cap of 18.6M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BNR trades at $17.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BNR's P/E ratio is -20.26. In terms of profitability, GRALV's ROE is N/A, compared to BNR's ROE of -0.13%. Regarding short-term risk, GRALV is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
GRALV vs CEMI Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GRALV's ROE is N/A, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GRALV is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
GRALV vs ENZ Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GRALV's ROE is N/A, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GRALV is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
GRALV vs PMD Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PMD's P/E ratio is -5.24. In terms of profitability, GRALV's ROE is N/A, compared to PMD's ROE of -0.32%. Regarding short-term risk, GRALV is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
GRALV vs ME Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ME's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to ME's ROE of -42.03%. Regarding short-term risk, GRALV is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
GRALV vs MYNZ Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GRALV's ROE is N/A, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, GRALV is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
GRALV vs CHEK Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GRALV's ROE is N/A, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GRALV is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
GRALV vs BIAFW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIAFW has a market cap of 9.8M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIAFW's P/E ratio is 1.04. In terms of profitability, GRALV's ROE is N/A, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, GRALV is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
GRALV vs CNTG Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GRALV's ROE is N/A, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GRALV is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
GRALV vs ADVB Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ADVB trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ADVB's P/E ratio is -61.18. In terms of profitability, GRALV's ROE is N/A, compared to ADVB's ROE of -0.21%. Regarding short-term risk, GRALV is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
GRALV vs NDRA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NDRA trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NDRA's P/E ratio is -0.88. In terms of profitability, GRALV's ROE is N/A, compared to NDRA's ROE of -2.25%. Regarding short-term risk, GRALV is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
GRALV vs APDN Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas APDN's P/E ratio is -0.10. In terms of profitability, GRALV's ROE is N/A, compared to APDN's ROE of -7.23%. Regarding short-term risk, GRALV is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
GRALV vs NVTA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GRALV is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
GRALV vs LMDX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GRALV is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
GRALV vs LMDXW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GRALV is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
GRALV vs DMTK Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GRALV's ROE is N/A, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GRALV is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
GRALV vs BIAF Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIAF has a market cap of 3.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BIAF trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIAF's P/E ratio is -0.87. In terms of profitability, GRALV's ROE is N/A, compared to BIAF's ROE of -2.57%. Regarding short-term risk, GRALV is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
GRALV vs NOTV Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GRALV is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
GRALV vs SQL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SQL's P/E ratio is -0.40. In terms of profitability, GRALV's ROE is N/A, compared to SQL's ROE of -30.46%. Regarding short-term risk, GRALV is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
GRALV vs AWH Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas AWH's P/E ratio is -0.09. In terms of profitability, GRALV's ROE is N/A, compared to AWH's ROE of +1.62%. Regarding short-term risk, GRALV is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
GRALV vs HTGM Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GRALV is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
GRALV vs BIOC Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GRALV is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
GRALV vs SQLLW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, GRALV is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
GRALV vs ISPC Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ISPC has a market cap of 165.2K. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while ISPC trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ISPC's P/E ratio is -0.04. In terms of profitability, GRALV's ROE is N/A, compared to ISPC's ROE of -5.24%. Regarding short-term risk, GRALV is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
GRALV vs WGSWW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, GRALV is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
GRALV vs DHR-PA Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GRALV's ROE is N/A, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
GRALV vs CHEKZ Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GRALV is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
GRALV vs OCDX Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GRALV's ROE is N/A, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GRALV is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
GRALV vs BNGOW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, GRALV is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
GRALV vs NDRAW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, GRALV is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
GRALV vs PRXL Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRXL's P/E ratio is 42.97. In terms of profitability, GRALV's ROE is N/A, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GRALV is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for GRALV.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
GRALV vs MEUSW Comparison September 2026
GRAIL, Inc. Common Stock (NASDAQ: GRALV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, GRALV is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for GRALV.Check MEUSW's competition here